Frequently asked questions on seven rare adverse events following immunization


adverse events
Guillain-Barré syndrome


Routine mass immunization programs have contributed greatly to the control of infectious diseases and to the improvement of the health of populations. Over the last decades, the rise of anti-vaccination movements has threatened the advances made in this field to the point that vaccination coverage rates have decreased and outbreaks of vaccine-preventable diseases have resurfaced.

One of the critical points of the immunization debate revolves around the level of risk attributable to vaccination, namely the possibility of experiencing serious and possibly irreversible adverse events. Unfortunately, the knowledge about adverse events, especially rare ones, is usually incomplete at best and the attribution of a causal relationship with vaccinations is subject to significant uncertainties.

The aim of this paper is to provide a narrative review of seven rare or very rare adverse events: hypotonic hyporesponsive episode, multiple sclerosis, apnea in pre-term newborns, Guillain-Barré syndrome, vasculitides, arthritis/arthralgia, immune thrombocytopenic purpura. We have selected these adverse events based on our experience of questions asked by health care workers involved in vaccination services. Information on the chosen adverse events was retrieved from Medline using appropriate search terms.

The review is in the form of questions and answers for each adverse event, with a view to providing useful and actionable concepts while not ignoring the uncertainties that remain. We also highlight in the conclusion possible future improvements to adverse event detection and assessment that could help identify individuals at higher risk against the probable future backdrop of ever-greater abandonment of compulsory vaccination policies.


WHO. Global Vaccine Action Plan 2011-2020.

Dubé E, Vivion M, MacDonald NE. Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications. Expert Rev Vaccines. 2015 Jan;14(1):99-117. doi: 10.1586/14760584.2015.964212.

Cameron KA, Roloff ME, Friesema EM, Brown T, Jovanovic BD, Hauber S, Baker DW. Pa-tient knowledge and recall of health information following exposure to "facts and myths" message format variations. Patient Educ Couns. 2013 Sep;92(3):381-7. doi: 10.1016/j.pec.2013.06.017. Last access: 30/08/2016

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code relating to medicinal products for human use.

Causality assessment of adverse event following immunization (AEFI): user manual for the revised WHO classification. WHO/HIS/EMP/QSS. MARCH 2013 glossary pag VIII

IOM (Institute of Medicine). 2012. Adverse effects of vaccines: Evidence and causality. Washington, DC: The National Academies Press.

Piano Nazionale Prevenzione Vaccinale 2016-2018 (Draft),, last access: 30/08/2016

WHO-UMC Glossary of terms used in Pharmacovigilance, March 2011,

International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline - clinical safety data management: definitions and standards for expedited reporting E2A, 27 October 1994,://

Vermeer-de Bondt PE, Dzaferagić A, David S, van der Maas NA. Performance of the Brighton collaboration case definition for hypotonic-hyporesponsive episode (HHE) on re-ported collapse reactions following infant vaccinations in the Netherlands. Vaccine. 2006 Nov 30;24(49-50):7066-70.

Braun MM, Terracciano G, Salive ME, Blumberg DA, Vermeer-de Bondt PE, Heijbel H, Evans G, Patriarca PA, Ellenberg SS. Report of a US public health service workshop on hypotonic-hyporesponsive episode (HHE) after pertussis immunization. Pediatrics. 1998 Nov;102(5):E52. doi:10.1542/peds.102.5.e52

Gold MS. Hypotonic-hyporesponsive episodes following pertussis vaccination: a cause for concern? Drug Saf. 2002;25(2):85-90. doi:10.2165/00002018-200225020-00003

Buettcher M, Heininger U, Braun M, Bonhoeffer J, Halperin S, Heijbel H, de Menezes Martins R, Vermeer-de Bondt P; Brighton Collaboration HHE Working Group. Hypo-tonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2007 Aug 1;25(31):5875-81. doi:10.1016/j.vaccine.2007.04.061

Goodwin H, Nash M, Gold M, Heath TC, Burgess MA. Vaccination of children following a previous hypotonic-hyporesponsive episode. J Paediatr Child Health. 1999 Dec;35(6):549-52. PubMed PMID: 10634981.

Monteiro SA, Takano OA, Waldman EA. Surveillance for adverse events after DTwP/Hib vaccination in Brazil: sensitivity and factors associated with reporting. Vac-cine. 2010 Apr 19;28(18):3127-33. doi:10.1016/j.vaccine.2010.02.059.

Kohl KS, Magnus M, Ball R, Halsey N, Shadomy S, Farley TA. Applicability, reliability, sensitivity, and specificity of six Brighton Collaboration standardized case definitions for adverse events following immunization. Vaccine. 2008 Nov 25;26(50):6349-60. doi:10.1016/j.vaccine.2008.09.002

Bonhoeffer J, Gold MS, Heijbel H, Vermeer P, Blumberg D, Braun M, de Souza-Brito G, Davis RL, Halperin S, Heininger U, Khuri-Bulos N, Menkes J, Nokleby H; Brighton Col-laboration HHE Working Group. Hypotonic-Hyporesponsive Episode (HHE) as an ad-verse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2004 Jan 26;22(5-6):563-8. doi:10.1016/j.vaccine.2003.09.009

Fotis L, Vazeou A, Xatzipsalti M, Stamoyannou L. Hypotonic hyporesponsive episode and the 13-valent pneumococcal vaccine. Turk J Pediatr. 2014 Jul-Aug;56(4):427-9.

Czajka H, Wysocki J. [Hypotonic-hyporesponsive episode (HHE) following vaccination with a combined vaccine against diphtheria, tetanus and pertussis (whole cell vaccine -DTPv)]. Neurol Neurochir Pol. 2004;38(1 Suppl 1):S17-24.

National Clinical Guideline Centre (UK). Multiple Sclerosis: Management of Multiple Scle-rosis in Primary and Secondary Care. London: National Institute for Health and Care Excel-lence (UK); 2014 Oct.

WHO. Atlas: Multiple Sclerosis Resources in the World 2008., available at

Ascherio A, Zhang SM, Hernán MA, Olek MJ, Coplan PM, Brodovicz K, Walker AM. Hep-atitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001 Feb 1;344(5):327-32. doi:10.1056/NEJM200102013440502

Touzé E, Gout O, Verdier-Taillefer MH, Lyon-Caen O, Alpérovitch A. [The first episode of central nervous system demyelinization and hepatitis B virus vaccination]. Rev Neurol (Par-is). 2000 Mar;156(3):242-6.

Langer-Gould A, Qian L, Tartof SY, Brara SM, Jacobsen SJ, Beaber BE, Sy LS, Chao C, Hechter R, Tseng HF. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014 Dec;71(12):1506-13. doi:10.1001/jamaneurol.2014.2633

Mikaeloff Y, Caridade G, Suissa S, Tardieu M. Hepatitis B vaccine and the risk of CNS in-flammatory demyelination in childhood. Neurology. 2009 Mar 10;72(10):873-80. doi:10.1212/01.wnl.0000335762.42177.07

Williamson EM, Chahin S, Berger JR. Vaccines in Multiple Sclerosis. Curr Neurol Neurosci Rep. 2016 Apr;16(4):36. doi: 10.1007/s11910-016-0637-6.

Eichenwald EC and AAP committee on fetus and newborn. Apnea of prematurity. Pediatrics 2016; 137(1):e20153757

Mathew OP. Apnea of prematurity: pathogenesis and management strategies. J Perinatol. 2011 May;31(5):302-10. doi: 10.1038/jp.2010.126

Slack MH, Schapira D. Severe apnoeas following immunisation in premature infants. Arch Dis Child Fetal Neonatal Ed. 1999 Jul;81(1):F67-8. doi:10.1136/fn.81.1.F67

Sánchez PJ, Laptook AR, Fisher L, Sumner J, Risser RC, Perlman JM. Apnea after immun-ization of preterm infants. J Pediatr. 1997 May;130(5):746-51. doi:10.1016/S0022-3476(97)80017-0

Botham SJ, Isaacs D. Incidence of apnoea and bradycardia in preterm infants follow-ing triple antigen immunization. J Paediatr Child Health. 1994 Dec;30(6):533-5. doi:10.1111/j.1440-1754.1994.tb00728.x

Botham SJ, Isaacs D, Henderson-Smart DJ. Incidence of apnoea and bradycardia in preterm infants following DTPw and Hib immunization: a prospective study. J Paediatr Child Health. 1997 Oct;33(5):418-21. PubMed PMID: 9401886.

Lee J, Robinson JL, Spady DW. Frequency of apnea, bradycardia, and desaturations follow-ing first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B im-munization in hospitalized preterm infants. BMC Pediatr. 2006 Jun 19;6:20. doi:10.1186/1471-2431-6-20

Pourcyrous M, Korones SB, Arheart KL, Bada HS. Primary immunization of premature in-fants with gestational age <35 weeks: cardiorespiratory complications and C-reactive protein responses associated with administration of single and multiple separate vaccines simultane-ously. J Pediatr. 2007 Aug;151(2):167-72.

Pourcyrous M, Korones SB, Crouse D, Bada HS. Interleukin-6, C-reactive protein, and ab-normal cardiorespiratory responses to immunization in premature infants. Pediatrics. 1998 Mar;101(3):E3. doi:10.1542/peds.101.3.e3

Cohen G, Lagercrantz H, Katz-Salamon M. Abnormal circulatory stress responses of preterm graduates. Pediatr Res. 2007 Mar;61(3):329-34. doi:10.1203/pdr.0b013e318030d0ef

Flatz-Jequier A, Posfay-Barbe KM, Pfister RE, Siegrist CA. Recurrence of cardiorespira-tory events following repeat DTaP-based combined immunization in very low birth weight premature infants. J Pediatr. 2008 Sep;153(3):429-31. doi:10.1016/j.jpeds.2008.03.043

Cooper PA, Madhi SA, Huebner RE, Mbelle N, Karim SS, Kleinschmidt I, Forrest BD, Klugman KP. Apnea and its possible relationship to immunization in ex-premature infants. Vaccine. 2008 Jun 25;26(27-28):3410-3. doi:10.1016/j.vaccine.2008.04.037

Sen S, Cloete Y, Hassan K, Buss P. Adverse events following vaccination in premature infants. Acta Paediatr. 2001 Aug;90(8):916-20. doi:10.1111/j.1651-2227.2001.tb02457.x

Pfister RE, Aeschbach V, Niksic-Stuber V, Martin BC, Siegrist CA. Safety of DTaP-based combined immunization in very-low-birth-weight premature infants: frequent but mostly be-nign cardiorespiratory events. J Pediatr. 2004 Jul;145(1):58-66. doi:10.1016/j.jpeds.2004.04.006

Slack MH, Schapira C, Thwaites RJ, Andrews N, Schapira D. Acellular pertussis and meningococcal C vaccines: cardio-respiratory events in preterm infants. Eur J Pediatr. 2003 Jun;162(6):436-7.

Faldella G, Galletti S, Corvaglia L, Ancora G, Alessandroni R. Safety of DTaP-IPV-HIb-HBV hexavalent vaccine in very premature infants. Vaccine. 2007 Jan 22;25(6):1036-42. doi:10.1016/j.vaccine.2006.09.065

Klein NP, Massolo ML, Greene J, Dekker CL, Black S, Escobar GJ; Vaccine Safety Datalink. Risk factors for developing apnea after immunization in the neonatal intensive care unit. Pe-diatrics. 2008 Mar;121(3):463-9. doi:10.1542/peds.2007-1462

Hacking DF, Davis PG, Wong E, Wheeler K, McVernon J. Frequency of respiratory dete-rioration after immunisation in preterm infants. J Paediatr Child Health. 2010 Dec;46(12):742-8 doi:10.1111/j.1440-1754.2010.01832.x

Gaudelus J, Lefèvre-Akriche S, Roumegoux C, Bolie S, Belasco C, Letamendia-Richard E, Lachassinne E. [Immunization of the preterm infant]. Arch Pediatr. 2007 Sep;14 Suppl 1:S24-30.

Esposito S, Serra D, Gualtieri L, Cesati L, Principi N. Vaccines and preterm neonates: why, when, and with what. Early Hum Dev. 2009 Oct;85(10 Suppl):S43-5. doi: 10.1016/j.earlhumdev.2009.08.011.

Saari TN; American Academy of Pediatrics Committee on Infectious Diseases. Immun-ization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics. 2003 Jul;112(1 Pt 1):193-8. doi:10.1542/peds.112.1.193

Clifford V, Crawford NW, Royle J, Lazzaro T, Danchin M, Perrett KP, Lee KJ, Buttery JP. Recurrent apnoea post immunisation: Informing re-immunisation policy. Vaccine. 2011 Aug 5;29(34):5681-7. doi:10.1016/j.vaccine.2011.06.005

Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012 Jun 14;366(24):2294-304. doi: 10.1056/NEJMra1114525

D'Alò GL, Ciabattini M, Zaratti L, Franco E. [Zika virus: a public health overview on epi-demiology, clinical practice and prevention]. Ig Sanita Pubbl. 2016 Mar-Apr;72(2):161-80.

Israeli E, Agmon-Levin N, Blank M, Chapman J, Shoenfeld Y. Guillain-Barré syndrome--a classical autoimmune disease triggered by infection or vaccination. Clin Rev Allergy Immunol. 2012 Apr;42(2):121-30. doi: 10.1007/s12016-010-8213-3

Louwen R, Horst-Kreft D, de Boer AG, van der Graaf L, de Knegt G, Hamersma M, Heikema AP, Timms AR, Jacobs BC, Wagenaar JA, Endtz HP, van der Oost J, Wells JM, Nieuwenhuis EE, van Vliet AH, Willemsen PT, van Baarlen P, van Belkum A. A novel link between Campylobacter jejuni bacteriophage defence, virulence and Guillain-Barré syndrome. Eur J Clin Microbiol Infect Dis. 2013 Feb;32(2):207-26. doi:10.1007/s10096-012-1733-4

Orlikowski D, Porcher R, Sivadon-Tardy V, Quincampoix JC, Raphaël JC, Durand MC, Sharshar T, Roussi J, Caudie C, Annane D, Rozenberg F, Leruez-Ville M, Gaillard JL, Gault E. Guillain-Barré syndrome following primary cytomegalovirus infection: a pro-spective cohort study. Clin Infect Dis. 2011 Apr 1;52(7):837-44. doi:10.1093/cid/cir074

Sivadon-Tardy V, Orlikowski D, Porcher R, Sharshar T, Durand MC, Enouf V, Rozenberg F, Caudie C, Annane D, van der Werf S, Lebon P, Raphaël JC, Gaillard JL, Gault E. Guil-lain-Barré syndrome and influenza virus infection. Clin Infect Dis. 2009 Jan 1;48(1):48-56. doi:10.1086/594124

Poser CM, Behan PO. Late onset of Guillain-Barré syndrome. J Neuroimmunol.1982 Aug;3(1):27-41.

Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009 Nov;5(11):648-52. doi:10.1038/nrrheum.2009.196

Tomljenovic L, Shoenfeld Y. Association between vaccination and Guillain-Barré syn-drome. Lancet Infect Dis. 2013 Sep;13(9):730-1. doi:10.1016/S1473-3099(13)70142-7

Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Saf. 2009;32(4):309-23. doi:10.2165/00002018-200932040-00005

Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol. 1979;110:105–23.

Geier MR, Geier DA, Zahalsky AC. Influenza vaccination and Guillain Barre syndrome. Clin Immunol. 2003 May;107(2):116-21.

Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inacti-vated influenza vaccines in adults: background for pandemic influenza vaccine safety moni-toring. Vaccine. 2009 Mar 26;27(15):2114-20. doi:10.1016/j.vaccine.2009.01.125.

Burwen DR, Ball R, Bryan WW, Izurieta HS, La Voie L, Gibbs NA, Kliman R, Braun MM. Evaluation of Guillain-Barré Syndrome among recipients of influenza vaccine in 2000 and 2001. Am J Prev Med. 2010 Oct;39(4):296-304. doi:10.1016/j.amepre.2010.05.022.

Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, Cunningham F, Garman P, Greene SK, Lee GM, Vellozzi C, Yih WK, Gellin B, Lurie N; H1N1 GBS Meta-Analysis Working Group. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013 Apr 27;381(9876):1461-8. doi:10.1016/S0140-6736(12)62189-8

Salmon DA, Halsey NA. Editorial commentary: Guillain-Barré syndrome and vaccina-tions. Clin Infect Dis. 2013 Jul;57(2):205-7. doi:10.1093/cid/cit218

Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, Zuber P, Hua W, Bonhoeffer J, Buttery J, Crawford N, Deceuninck G, de Vries C, De Wals P, Gutierrez-Gimeno MV, Heijbel H, Hughes H, Hur K, Hviid A, Kelman J, Kilpi T, Chuang SK, Macart-ney K, Rett M, Lopez-Callada VR, Salmon D, Gimenez-Sanchez F, Sanz N, Silverman B, Storsaeter J, Thirugnanam U, van der Maas N, Yih K, Zhang T, Izurieta H; Global H1N1 GBS Consortium. International collaboration to assess the risk of Guillain Barré Syn-drome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine. 2013 Sep 13;31(40):4448-58. doi:10.1016/j.vaccine.2013.06.032

Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M; VAESCO-GBS Case-Control Study Group. Guillain-Barre syndrome and adjuvanted pandemic in-fluenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ. 2011 Jul 12;343:d3908. doi:10.1136/bmj.d3908

Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guil-lain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol. 2009 Feb 1;169(3):382-8. doi:10.1093/aje/kwn310+

Poland GA, Poland CM, Howe CL. Influenza vaccine and Guillain-Barré syndrome: mak-ing informed decisions. Lancet. 2013 Apr 27;381(9876):1437-9. doi:10.1016/S0140-6736(13)60182-8

Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vac-cination: the epidemiologic evidence. Clin Infect Dis. 2014 Apr;58(8):1149-55. doi:10.1093/cid/ciu005

Vellozzi C, Iqbal S, Stewart B, Tokars J, DeStefano F. Cumulative risk of Guillain-Barré syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 in-fluenza pandemic. Am J Public Health. 2014 Apr;104(4):696-701. doi:10.2105/AJPH.2013.301651

Martín Arias LH, Sanz R, Sáinz M, Treceño C, Carvajal A. Guillain-Barré syndrome and influenza vaccines: A meta-analysis. Vaccine. 2015 Jul 17;33(31):3773-8. doi:10.1016/j.vaccine.2015.05.013

Hawken S, Kwong JC, Deeks SL, Crowcroft NS, McGeer AJ, Ducharme R, Campitelli MA, Coyle D, Wilson K. Simulation study of the effect of influenza and influenza vaccination on risk of acquiring Guillain-Barré syndrome. Emerg Infect Dis. 2015 Feb;21(2):224-31. doi:10.3201/eid2102.131879

Andrews N, Stowe J, Al-Shahi Salman R, Miller E. Guillain-Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the Unit-ed Kingdom: self-controlled case series. Vaccine. 2011 Oct 19;29(45):7878-82. doi:10.1016/j.vaccine.2011.08.069

Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ; Centers for Disease Control and Prevention (CDC). Preven-tion and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62. Erratum in: MMWR Recomm Rep. 2010 Aug 13;59(31):993. MMWR Recomm Rep. 2010 Sep 10;59(35):1147.

Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA. Recurrences, vac-cinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst. 2009 Dec;14(4):310-5. doi: 10.1111/j.1529-8027.2009.00243.x.

Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic vasculitis--is it time to reclassify? Rheumatology (Oxford). 2011 Apr;50(4):643-5. doi:10.1093/rheumatology/keq229.

Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002 Oct 19;360(9341):1197-202. doi:10.1016/S0140-6736(02)11279-7

Bonetto C, Trotta F, Felicetti P, Alarcón GS, Santuccio C, Bachtiar NS, Brauchli Pernus Y, Chandler R, Girolomoni G, Hadden RD, Kucuku M, Ozen S, Pahud B, Top K, Varricchio F, Wise RP, Zanoni G, Živković S, Bonhoeffer J; Brighton Collaboration Vasculitis Working Group. Vasculitis as an adverse event following immunization - Systematic literature review. Vaccine. 2015 Sep 21. doi:10.1016/j.vaccine.2015.09.026

de Carvalho JF, Pereira RM, Shoenfeld Y. Systemic polyarteritis nodosa following hepa-titis B vaccination. Eur J Intern Med. 2008 Dec;19(8):575-8. doi:10.1016/j.ejim.2007.06.035

Shoenfeld Y, Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011 Feb;36(1):4-8. doi:10.1016/j.jaut.2010.07.003

Agmon-Levin N, Hughes GR, Shoenfeld Y. The spectrum of ASIA: 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants'. Lupus. 2012 Feb;21(2):118-20. doi: 10.1177/0961203311429316. PubMed PMID: 22235040.

Zafrir Y, Agmon-Levin N, Paz Z, Shilton T, Shoenfeld Y. Autoimmunity following hepati-tis B vaccine as part of the spectrum of 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants' (ASIA): analysis of 93 cases. Lupus. 2012 Feb;21(2):146-52. doi:10.1177/0961203311429318

Toubi E. ASIA-autoimmune syndromes induced by adjuvants: rare, but worth consid-ering. Isr Med Assoc J. 2012 Feb;14(2):121-4.

Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Auto-immune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 2013 Dec;47:1-16. doi:10.1016/j.jaut.2013.10.004

Hehn J, Hartmann K, Bröcker EB, Goebeler M. [Influenza vaccination and skin disease--coincidence or causal association?]. J Dtsch Dermatol Ges. 2003 Feb;1(2):99-104.

Soriano A, Verrecchia E, Marinaro A, Giovinale M, Fonnesu C, Landolfi R, Manna R. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus. 2012 Feb;21(2):153-7. doi:10.1177/0961203311430222

Hua W, Izurieta HS, Slade B, Belay ED, Haber P, Tiernan R, Woo EJ, Iskander J, Braun MM, Ball R. Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007. Pediatr Infect Dis J. 2009 Nov;28(11):943-7. doi: 10.1097/INF.0b013e3181a66471

EMA Bexsero public assessment report

Abrams JY, Weintraub ES, Baggs JM, McCarthy NL, Schonberger LB, Lee GM, Klein NP, Belongia EA, Jackson ML, Naleway AL, Nordin JD, Hambidge SJ, Belay ED. Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006. Vaccine. 2015 Jan 3;33(2):382-7. doi:10.1016/j.vaccine.2014.10.044

Gatto M, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal R, Kivity S, Doria A, Shoen-feld Y. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol. 2013 Sep;32(9):1301-7. doi: 10.1007/s10067-013-2266-7.

Guillevin L. Infections in vasculitis. Best Pract Res Clin Rheumatol. 2013 Feb;27(1):19-31. doi:10.1016/j.berh.2013.01.004

Piram M, Mahr A. Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge. Curr Opin Rheumatol. 2013 Mar;25(2):171-8. doi:10.1097/BOR.0b013e32835d8e2a

James M. Rippe, Encyclopedia of Lifestyle Medicine and Health, 2011, pag 81, last access 29/07/2016

Centers for Disease Control and Prevention (CDC). Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2010-2012. MMWR Morb Mortal Wkly Rep. 2013 Nov 8;62(44):869-73

Gualberto FA, Curti SP, de Oliveira MI, Moraes-Vasconcelos D, Figueiredo CA. In-termittent rash, lymph node swelling, arthralgia and vaccinal viral detection after rubella im-munization. J Clin Virol. 2013 Feb;56(2):93-5. doi: 10.1016/j.jcv.2012.07.017.

Sukumaran L, McNeil MM, Moro PL, Lewis PW, Winiecki SK, Shimabukuro TT. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013. Clin Infect Dis. 2015 May 15;60(10):e58-65. doi:10.1093/cid/civ061

Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005 Jun 10;23(30):3876-86.

Toussirot É, Bereau M. Vaccination and Induction of Autoimmune Diseases.Inflamm Allergy Drug Targets. 2015;14(2):94-8.

Slater PE, Ben-Zvi T, Fogel A, Ehrenfeld M, Ever-Hadani S. Absence of an associa-tion between rubella vaccination and arthritis in underimmune postpartum women. Vaccine 1995;13:1529–32.

Ray P, Black S, Shinefield H, Dillon A, Schwalbe J, Holmes S, Hadler S, Chen R, Cochi S, Wassilak S. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. JAMA. 1997 Aug 20;278(7):551-6.

van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M. EULAR recommendations for vac-cination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011 Mar;70(3):414-22. doi:10.1136/ard.2010.137216

Bijl M, Agmon-Levin N, Dayer JM, Israeli E, Gatto M, Shoenfeld Y. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev. 2012 Jun;11(8):572-6. doi:10.1016/j.autrev.2011.10.015

Perricone C, Agmon-Levin N, Valesini G, Shoenfeld Y. Vaccination in patients with chronic or autoimmune rheumatic diseases: the ego, the id and the superego. Joint Bone Spine. 2012 Jan;79(1):1-3. doi:10.1016/j.jbspin.2011.10.006

Thomas C, Moridani M. Interindividual variations in the efficacy and toxicity of vaccines. Toxicology. 2010 Dec 5;278(2):204-10. doi:10.1016/j.tox.2009.10.008

Nerome Y, Akaike H, Nonaka Y, Takezaki T, Kubota T, Yamato T, Yamasaki Y, Imanaka H, Kawano Y, Takei S. The safety and effectiveness of HBV vaccination in pa-tients with juvenile idiopathic arthritis controlled by treatment. Mod Rheumatol. 2016 May;26(3):368-71. doi: 10.3109/14397595.2015.1085608.

Rákóczi É, Perge B, Végh E, Csomor P, Pusztai A, Szamosi S, Bodnár N, Szántó S, Szücs G, Szekanecz Z. Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept. Joint Bone Spine. 2016 Mar 16. pii: S1297-319X(16)00043-9. doi:10.1016/j.jbspin.2015.10.017.

Alten R, Bingham CO 3rd, Cohen SB, Curtis JR, Kelly S, Wong D, Genovese MC. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet Disord. 2016 May 26;17:231. doi: 10.1186/s12891-016-1082-z.

Grimaldi-Bensouda L, Michel M, Aubrun E, Leighton P, Viallard JF, Adoue D, Magy-Bertrand N, Tisserand G, Khellaf M, Durand JM, Quittet P, Fain O, Bonnotte B, Morin AS, Limal N, Costedoat-Chalumeau N, Morel N, Pan-Petesch B, Decaux O, Mahe-vas M, Ruel M, Sacre K, Lefrere F, Abenhaim L, Godeau B; PGRx Immune Thrombocy-topenia Study Group. A case-control study to assess the risk of immune thrombocyto-penia associated with vaccines. Blood. 2012 Dec 13;120(25):4938-44. doi:10.1182/blood-2012-05-431098

Cecinati V, Principi N, Brescia L, Giordano P, Esposito S. Vaccine administration and the development of immune thrombocytopenic purpura in children. Hum Vaccin Immunother. 2013 May;9(5):1158-62. doi:10.4161/hv.23601

Woo EJ, Wise RP, Menschik D, Shadomy SV, Iskander J, Beeler J, Varricchio F, Ball R. Thrombocytopenia after vaccination: case reports to the US Vaccine Adverse Event Reporting System, 1990-2008. Vaccine. 2011 Feb 1;29(6):1319-23. doi:10.1016/j.vaccine.2010.11.051

Sauvé LJ, Scheifele D. Do childhood vaccines cause thrombocytopenia? Paediatr Child Health. 2009 Jan;14(1):31-2.

Rejjal AL, Britten G, Nazer H. Thrombocytopenic purpura following measles-mumps-rubella vaccination. Ann Trop Paediatr. 1993;13(1):103-4.

Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after mea-sles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr. 2010 Apr;156(4):623-8. doi:10.1016/j.jpeds.2009.10.015

Fujita H. [Idiopathic thrombocytopenic purpura following viral infection].Nihon Rinsho. 2003 Apr;61(4):650-4.

Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematolo-gy Am Soc Hematol Educ Program. 2012;2012:306-12. doi: 10.1182/asheducation-2012.1.306

Okazaki N, Takeguchi M, Sonoda K, Handa Y, Kakiuchi T, Miyahara H, Akiyoshi K, Korematsu S, Suenobu S, Izumi T. Detection of platelet-binding anti-measles and anti-rubella virus IgG antibodies in infants with vaccine-induced thrombocytopenic purpu-ra. Vaccine. 2011 Jul 12;29(31):4878-80. doi:10.1016/j.vaccine.2011.04.036

Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun. 2001 May;16(3):309-18. doi:10.1006/jaut.2000.0491

Meyboom RH, Fucik H, Edwards IR. Thrombocytopenia reported in association with hepatitis B and A vaccines. Lancet. 1995 Jun 24;345(8965):1638. doi:10.1016/S0140-6736(95)90143-4

France EK, Glanz J, Xu S, Hambidge S, Yamasaki K, Black SB, Marcy M, Mullooly JP, Jackson LA, Nordin J, Belongia EA, Hohman K, Chen RT, Davis R; Vaccine Safety Dat-alink Team. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics. 2008 Mar;121(3):e687-92. doi:10.1542/peds.2007-1578

Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpu-ra. Br J Clin Pharmacol. 2003 Jan;55(1):107-11. doi:10.1046/j.1365-2125.2003.01790.x

Nieminen U, Peltola H, Syrjälä MT, Mäkipernaa A, Kekomäki R. Acute thrombo-cytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr. 1993 Mar;82(3):267-70. doi:10.1111/j.1651-2227.1993.tb12657.x

Jonville-Béra AP, Autret E, Galy-Eyraud C, Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and pasteur-mérieux sérums et vaccins. Pediatr Infect Dis J. 1996 Jan;15(1):44-8. doi:10.1097/00006454-199601000-00010

Ozsoylu S, Kanra G, Savaş G. Thrombocytopenic purpura related to rubella in-fection. Pediatrics. 1978 Oct;62(4):567-9.

Chang S, O'Connor PM, Slade BA, Woo EJ. U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007. Vaccine. 2013 Feb 27;31(10):1447-52. doi: 10.1016/j.vaccine.2012.10.097.

Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 2001 Mar;84(3):227-9

Sladden RA. Thrombocytopenic purpura and rubella. Br Med J. 1963 Dec 21;2(5372):1587-8.

Morse EE, Zinkham WH, Jackson DP. Thrombocytopenic purpura following ru-bella infection in children and adults. Arch Intern Med. 1966 Apr;117(4):573-9.

Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 Mar 12;113(11):2386-93. doi:10.1182/blood-2008-07-162503

O'Leary ST, Glanz JM, McClure DL, Akhtar A, Daley MF, Nakasato C, Baxter R, Davis RL, Izurieta HS, Lieu TA, Ball R. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics. 2012 Feb;129(2):248-55. doi:10.1542/peds.2011-1111

Vlacha V, Forman EN, Miron D, Peter G. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics. 1996 May;97(5):738-9.

Drachtman RA, Murphy S, Ettinger LJ. Exacerbation of chronic idiopathic thrombocytopenic purpura following measles-mumps-rubella immunization. Arch Pe-diatr Adolesc Med. 1994 Mar;148(3):326-7. doi:10.1001/archpedi.1994.02170030096023

British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol. 2003 Jul;122(1):10-23.

Bibby AC, Farrell A, Cummins M, Erlewyn-Lajeunesse M. Is MMR immunisation safe in chronic Idiopathic thrombocytopenic purpura? Arch Dis Child. 2008 Apr;93(4):354-5. doi:10.1136/adc.2007.132340

Moulis G, Lapeyre-Mestre M, Mahévas M, Montastruc JL, Sailler L. Need for an im-proved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol. 2015 Apr;90(4):301-5. doi: 10.1002/ajh.23930., last access: 26-08-2016

Horowitz, Julia (30 June 2015). "California governor signs strict school vaccine legis-lation". Associated Press. Retrieved 30 June 2015

Betsch C, Böhm R. Detrimental effects of introducing partial compulsory vaccination: experimental evidence. Eur J Public Health. 2016 Jun;26(3):378-81. doi: 10.1093/eurpub/ckv154.

Austin Bradford Hill, “The Environment and Disease: Association or Causa-tion?, ”Proceedings of the Royal Society of Medicine, 58 (1965), 295-300

Scherer LD, Shaffer VA, Patel N, Zikmund-Fisher BJ. Can the vaccine adverse event reporting system be used to increase vaccine acceptance and trust? Vaccine. 2016 May 5;34(21):2424-9. doi: 10.1016/j.vaccine.2016.03.087.

Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, Cook AR, Jones NS. The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey. EBioMedicine, available online 13 September 2016, DOI: